2 completed, 1 active not recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Active not recruiting 1 |
Follow 68ga-Psma: new trials by email Literature Review of 68ga-Psma trials Research Report on 68ga-Psma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 3 | Completed | Mayo Clinic | 163 | 2022-05-09 | 2025-07-18 |
| Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy Best Practice, Computed Tomography, Gallium Ga 68-labeled PSMA-11 - Recurrent Prostate Carcinoma | Phase 3 | Active not recruiting | Jonsson Comprehensive Cancer Center | 193 | 2018-07-12 | 2026-05-26 |
| Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy Gallium Ga 68 Gozetotide, Laboratory Biomarker Analysis, Positron Emission Tomography - Prostate Adenocarcinoma, Recurrent Prostate Carcinoma | Phase 3 | Completed | Jonsson Comprehensive Cancer Center | 1138 | 2016-09-15 | 2021-07-02 |
Jonsson Comprehensive Cancer Center (2) · Mayo Clinic (1)
United States (3)
Geoffrey B. Johnson, M.D., Ph.D. (1) · Jeremie Calais (1) · Johannes Czernin, MD (1)
PMID 41698328, PMID 29242398, PMID 29242404, PMID 30616601, PMID 30920593, PMID 31375469, PMID 32808077, PMID 33386288